Effect of pentoxiphylline on survival, cardiac function, and portal and systemic hemodynamics in advanced alcoholic cirrhosis;Efecto de la pentoxifilina en la supervivencia, la función cardiaca y en la hemodinámica portal y sistémica de la cirrosis alcohólica avanzada

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 8, 2008, Pages 481-489

  Fernández Rodríguez, Conrado M ^a   Lledo J L ^a   Lopez Serrano P ^a   Gutierrez M L ^a   Alonso, S ^a   Perez Fernandez M T ^a   Fernandez Gil M ^a   Pazos, R ^a   Tolon, R ^a   Hernandez T ^a   Sanz, P ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Cirrhotic cardyomyopathy; Haemodynamics; Human cirrhosis; TNF inhibition

Indexed keywords

PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANOREXIA; ANXIETY; ARTICLE; BLOOD TOXICITY; BLURRED VISION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; EPISTAXIS; FEMALE; HEART FUNCTION; HEMODYNAMICS; HUMAN; MALE; MIGRAINE; OUTCOME ASSESSMENT; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; VASCULAR RESISTANCE; VOMITING; DRUG ANTAGONISM; DRUG EFFECT; HEART; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PORTAL VEIN; SURVIVAL RATE;

DOUBLE-BLIND METHOD; FEMALE; HEART; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PENTOXIFYLLINE; PORTAL SYSTEM; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57549097239     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Groszman RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.
2. Martin PY, Schrier RW. Pathogenesis of water and sodium retention in cirrhosis. Kidney Int Suppl 1997; 59: S43-9.
3. Ginés P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175-89.
4. Shapiro MD, Nicholls KM, Groves BM, Kluge R, Chung HM, Bichet DG, et al. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int 1985; 2: 206-11.
5. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
6. Llach J, Ginês P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
7. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999; 97: 259-67.
8. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-9.
9. Möller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
10. Möller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis: pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785-94.
11. Ma Z, Lee SS, Meddingd JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997; 26: 904-12.
12. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 18: 937-44.
13. López-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszman RJ. Thalidomide inhibits tumor necrosis factor-?, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996; 23: 1616-21.
14. Wiest R, Das S, Cadelina G, García-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
15. Wiest R, Cadelina G, Milstien S, McCuskey RS, García-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-15.
16. López-Talavera JC, Merrill W, Groszmann RJ. Tumor necrosis factor-alpha: a major contributor to the hyperdynamic circulation in prehepatic portal hypertensive rats. Gastroenterology 1995; 108: 761-7.
17. Genescà J, Martí R, Rojo F, Campos F, Peribáñ ez V, González A, Castells I, et al. Increased tumour necrosis factor-production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003; 52: 1054-9.
18. Bataller R, Brenner D. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
19. Cogni A, Paul JL, Durbled B, Atger V, Lenoble M, Moatti N. Oxidative modification of high density lipoprotein 3 induced by human polimorphonuclear neutrophils. Protective effect of pentoxifylline. Eur J Biochem 1999; 259: 32-9.
20. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakill O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.
21. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sarelli P. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-3.
22. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
23. Elefthearidis E, Kotzampassi K, Koufogianis D. Modulation of intravariceal pressure with pentoxifylline: a possible new approach in the treatment of portal hypertension. Am J Gastroenterol 1998; 93: 2431-5.
24. Labovitz AJ, Buckingham TA, Habermehl K, Nelson J, Kennedy HL, Williams GA. The effects of sampling site on the two-dimensional echo-Doppler determination of cardiac output. Am Heart J 1985; 109: 327-32.
25. McLennan FM, Haites NE, Mackenzie JD, Daniel MK, Rawles JM. Reproducibility of linear cardiac output measurement by Doppler ultrasound alone. Br Heart J 1986; 55: 25-31.
26. Julius S. Validation of non-invasive measurement of cardiac output. The Ann Arbor experience. Eur Heart J 1990; 11: 144-7.
27. De Simone G, Devereux RB, Ganau A, Hahn RT, Saba PS, Mureddu GF, Roman MJ, et al. Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol 1996; 78: 801-7.
28. Reichek N, Wilson J, St John Sutton M, Plappert TA, Goldberg S, Hirshfeld JW. Noninvasive determination of left ventricular endsystolic stress: validation of the method and initial application. Circulation 1982; 65: 99-108.
29. Iwao T, Oho K, Sakai T, Sato M, Nakano R, Yamayaki M, Toyonaga A, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 1998; 28: 847-55.
30. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia-Brandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004; 41: 229-34.
31. Ginès P, Schrier RW. Hepatorenal syndrome and renal dysfunction associated with liver disease. In: Schrier RW, Gottschalk CW, editors. Diseases of the kidney. Volume 3. 6th ed. Boston: Little Brown; 1997. p. 2099-127.
32. Møller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis: relations to splanchnic and systemic hemodynamics. J Hepatol 1997; 27: 284-94.
33. Fernández-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodríguez Eire JL, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304-12.
34. Clària J, Jiménez W, Ros J, Asbert M, Castro A, Arroyo V, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15: 343-9.
35. Fernández-Rodríguez CM, Prieto J, Zozaya JM, Quiroga J, Guitán R. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology 1993; 104: 1139-45.
36. Sánchez S, Albornoz L, Bandi JC, Gerona S, Mastai R. Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis. Eur J Gastroenterol Hepatol 1997; 7: 27-31.
37. Feu F, García-Pagán JC, Ruiz del Árbol L, Cirera J, Pizcueta P, Bosch J. Lack of effect of pentoxifylline on portal pressure and hepatic hemodynamics in cirrhosis. J Hepatol 1990; 10: S87 (Abstract).
38. Grange J, Jaillon P, Noblinski B. La pentoxifylline: un traitment potentiel des cirroses avec hipertensión portale? Gastroenterol Clin Biol 1987; 11: 161 A (Abstract).
39. Dagenais M, Pomier-Layrargues G, Rocheleau B, Giroux I, Huet PM. Systemic and splanchnic hemodynamic effects of pentoxifylline in rats with portal hypertension. Clin Sci 1992; 83: 41-5.
40. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004; 19: 79-88.